Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of G03-52-01 in Healthy Adults
NCT05348993Phase 2Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Jun 2022
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of G03-52-01 in botulism, sponsored by U.S. Army Medical Research and Development Command. Started Jun 2022; status: completed.
02
Drugs
G03-52-01
03
Conditions
botulism
Beyond the preview
Go deeper on NCT05348993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05348993.